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Summary
 
The natural killer T (NKT) cell ligand 
 
a
 
-galactosylceramide (
 
a
 
-GalCer) exhibits profound an-
titumor activities in vivo that resemble interleukin (IL)-12–mediated antitumor activities. Be-
cause of these similarities between the activities of 
 
a
 
-GalCer and IL-12, we investigated the in-
volvement of IL-12 in the activation of NKT cells by 
 
a
 
-GalCer. We first established, using
purified subsets of various lymphocyte populations, that 
 
a
 
-GalCer selectively activates NKT
cells for production of interferon (IFN)-
 
g
 
. Production of IFN-
 
g
 
 by NKT cells in response to
 
a
 
-GalCer required IL-12 produced by dendritic cells (DCs) and direct contact between NKT
cells and DCs through CD40/CD40 ligand interactions. Moreover, 
 
a
 
-GalCer strongly in-
duced the expression of IL-12 receptor on NKT cells from wild-type but not CD1
 
2
 
/
 
2
 
 or
V
 
a
 
14
 
2
 
/
 
2
 
 mice. This effect of 
 
a
 
-GalCer required the production of IFN-
 
g
 
 by NKT cells and
production of IL-12 by DCs. Finally, we showed that treatment of mice with suboptimal doses
of 
 
a
 
-GalCer together with suboptimal doses of IL-12 resulted in strongly enhanced natural
killing activity and IFN-
 
g
 
 production. Collectively, these findings indicate an important role
for DC-produced IL-12 in the activation of NKT cells by 
 
a
 
-GalCer and suggest that NKT
cells may be able to condition DCs for subsequent immune responses. Our results also suggest
a novel approach for immunotherapy of cancer. 
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interleukin 12 receptor
 
N
 
atural killer T (NKT)
 
1
 
 cells represent a novel lym-
phoid lineage distinct from mainstream T cells, B
cells, and NK cells. NKT cells are characterized by the ex-
pression of an invariant TCR encoded by V
 
a
 
14 and J
 
a
 
281
gene segments and V
 
b
 
8, 7, or 2 gene segments (1, 2). It
was demonstrated recently that NKT cells are strongly
stimulated by the glycolipid 
 
a
 
-galactosylceramide (
 
a
 
-Gal-
Cer), a potent inducer of antitumor immunity in mice
(3–5). Recognition of 
 
a
 
-GalCer by NKT cells appeared to
depend on the interaction of the invariant TCR of these
cells with 
 
a
 
-GalCer presented by the nonclassical MHC
molecule CD1d on APCs (6). Stimulation of NKT cells by
 
a
 
-GalCer resulted in the production of large amounts of
IFN-
 
g
 
 and some IL-4, and the development of a cytotoxic
phenotype (7).
The in vivo antitumor activity of 
 
a
 
-GalCer strongly re-
sembles the antitumor activity mediated by the cytokine
IL-12 (8, 9). Moreover, both 
 
a
 
-GalCer and IL-12 are
 
1
 
Abbreviations used in this paper:
 
 
 
a
 
-GalCer, 
 
a
 
-galactosylceramide; DC, den-
dritic cell; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NKT,
natural killer T; RT, reverse transcription. 
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strong inducers of NKT cell activity and exert their antitu-
mor activities through activation of these cells (8, 9). Be-
cause of these striking similarities between 
 
a
 
-GalCer and
IL-12 for activation of NKT cells, we decided to investi-
gate whether 
 
a
 
-GalCer activation of NKT cells involves
regulation by IL-12. First, we demonstrated that NKT cells
are the main, if not the only, target for activation by 
 
a
 
-Gal-
Cer in spleen cell populations of mice. Second, we showed
that endogenous IL-12 produced by dendritic cells (DCs) is
critically important for the activation of NKT cells by
 
a
 
-GalCer and that the interaction between DCs and NKT
cells involves CD40 and its ligand. Third, 
 
a
 
-GalCer in-
duced the expression of IL-12R on NKT cells, which re-
quired the production of IFN-
 
g
 
 by NKT cells. Fourth,
 
a
 
-GalCer acted synergistically with IL-12 in the activation
of natural killing activity and IFN-
 
g
 
 production in vivo.
Collectively, these findings indicate that 
 
a
 
-GalCer exerts
its function through IL-12 and suggest a novel approach
for therapeutic intervention in cancer and other disease
processes.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice were purchased from Charles River Ja-
pan. V
 
a
 
14 NKT cell–deficient (J
 
a
 
281
 
2
 
/
 
2
 
) and CD1d
 
2
 
/
 
2
 
 mice
were established by specific deletion of the J
 
a
 
281 and CD1d
gene segment, respectively (3, 10). All mice used in this study
were at 5–8 wk of age and were maintained in specific pathogen–
free conditions.
 
a
 
-GalCer.
 
a
 
-GalCer [(2S,3S,4R)-1-
 
O
 
-(
 
a
 
-
 
d
 
-galactopyran-
osyl)-2-(
 
N
 
-hexacosanoylamino)-1,3,4-octadecanetriol] used for
this study was provided by Dr. Y. Koezuka (Kirin Brewery Co.,
Ltd., Gunma, Japan [4, 5]). The stock solution of 
 
a
 
-GalCer (220
 
m
 
g/ml) was diluted in 0.5% polysorbate 20 (Nikko Chemical) in
0.9% NaCl solution. This stock solution was further diluted into
an appropriate concentration with saline and used for the experi-
ments. A vehicle control solution was prepared from a solution of
0.5% polysorbate 20 in 0.9% NaCl solution. The vehicle control
was used in all experiments.
 
Isolation of Lymphoid Cell Subsets by FACS
 
®
 
.
 
Spleen cells were
incubated on nylon wool columns for 45 min, and the nonadher-
ent cells were used for the isolation of NKT cells, NK cells,
CD4
 
1
 
 T cells, and CD8
 
1
 
 T cells by cell sorting using a FACS
Vantage™ instrument (Becton Dickinson). All mAbs used in
these experiments (mAbs against NK1.1, CD4, CD8, and TCR-
 
a
 
/
 
b
 
) were purchased from PharMingen. Unless noted otherwise,
NK1.1
 
1
 
TCR-
 
a
 
/
 
b
 
1
 
 cells were used as purified NKT cells. The
stained cells were isolated using the FACS Vantage™. The purity
of the sorted cells was 
 
.
 
98%. The details of the staining and sort-
ing have been described previously (11).
 
Coculture of DCs and NKT Cells.
 
DCs were prepared accord-
ing to the method of Steinman et al. (12) with some modifica-
tions. In brief, spleen cells were incubated in 10-cm plastic dishes
(Falcon; Becton Dickinson) for 2 h, and the nonadherent cells
were removed from the culture. The adherent cells were further
incubated overnight and the nonadherent cells were harvested.
Then, CD11c
 
1
 
B220
 
2
 
CD4
 
2
 
CD8
 
2
 
 cells were isolated from the
nonadherent populations by cell sorting and used as the source
of DCs. Generally, DCs (10
 
5
 
) were cocultured with purified
NK1.1
 
1
 
TCR-
 
a
 
/
 
b
 
1
 
 NKT cells (2 
 
3
 
 10
 
5
 
) in the presence of 50
ng/ml of 
 
a
 
-GalCer in 96-well U-bottomed plates (Costar
 
Corp.). After incubation for 36 h, the culture supernatants were
harvested to detect cytokine levels.
 
Detection of Cytokine Activity.
 
IL-4 or IFN-
 
g
 
 activity in cul-
ture supernatants was determined using the Biotrac™ mouse IL-4
or Biotrac™ mouse IFN-
 
g
 
 ELISA system (Nycomed Amersham
plc). Serum samples were obtained from C57BL/6 mice 24 h af-
ter injection of 
 
a
 
-GalCer (200 ng/mouse) and/or IL-12 (200
U/mouse; donated by Genetics Institute, Inc., Cambridge, MA),
and cytokine levels were measured using ELISA kits (Nycomed
Amersham plc). IL-12 p70 activity in culture supernatants was
measured using Intertest-12X™
 
 
 
ELISA kits (Genzyme Corp.).
 
Cytotoxicity Assay.
 
The natural killing activity of spleen cells
was determined by 4-h 
 
51
 
Cr-release assays using YAC-1 cells as
target. 1 lytic unit (LU) was defined as the number of effector
cells required to cause 25% lysis of 2,500 target cells as described
previously (13).
 
Measurement of the Synergistic Effect of 
 
a
 
-GalCer and IL-12 In Vivo.
 
Wild-type C57BL/6 mice received an injection of 
 
a-GalCer (200
ng/mouse i.v.), and 6 h later mice were injected with recombinant
IL-12 (200 U/mouse i.p.) or saline. 1 d after treatment with IL-12,
IFN-g production in the serum and NK activity of spleen cells
were determined. Control mice were treated with vehicle only.
Quantitative Reverse Transcription PCR Assay for IL-12R mRNA
Measurement. C57BL/6, CD1d2/2, and Va14 NKT cell–defi-
cient mice were injected with a-GalCer (2 mg/mouse i.v.) or ve-
hicle. At different time points (0–6 h) after treatment, mice were
killed and spleen cells were isolated. TaqMan™ real-time quantita-
tive reverse transcription (RT)-PCR assay was carried out for the
detection of IL-12R mRNA expression by these cells according
to published methods (14). In brief, total RNA extracts from the
cells were added to the master mixture. To detect the amount of
the IL-12R mRNA RT-PCR amplificon, target (IL-12Rb1,
IL-12Rb2) and control (glyceraldehyde 3-phosphate dehydroge-
nase [GAPDH]) hybridization probes were mixed with target and
control PCR primers, respectively. This mixture was transferred
to a set of thermocycler tubes and transcribed at 428C for 30 min,
followed by 40 cycles of amplification at 958C for 15 s and 608C
for 1.5 min, and analyzed using an ABI PRISM 7700 sequence
detector (Applied Biosystems). IL-12Rb1 and IL-12Rb2 mRNA
expression were estimated from the ratio of fluorescence intensity
to GAPDH. IL-12R expression induced by a-GalCer is indi-
cated in the figures as induction index, calculated as follows: in-
duction index 5 IL-12R expression of a-GalCer–stimulated
sample/IL-12R expression of unstimulated sample.
TaqMan™ probes used for these analyses are as follows:
IL-12Rb1 mRNA-605T, 59-CGGATGCCCACAACGAAT-
TGGA-39; IL-12Rb2 mRNA-551T, 59-AGCCACCTCAAAA-
CATATCATGTGTCCAGG-39; GAPDH-542T, 59-CCTGGC-
CAAGGTCATCCATGACAACTTT-39.
PCR primers used for these analyses are as follows: IL-12b1
mRNA, forward primer (-563F) 59-AATGTGTCTGAAGAGGC-
CGGT-39 and reverse primer (-657R) 59-GAGTTAACCTGAG-
GTCCGCAGT-39; IL-12Rb2 mRNA, forward primer (-529F)
59-ATCTCAGTTGGTGTTGCTCCA-39 and reverse primer
(-602R) 59-GCCACAGTTCCATTTTCTCCT-39; GAPDH, for-
ward primer (-368F) 59-CTTCACCACCATGGAGAAGGC-39
and reverse primer (-605R) 59-GGCATGGACTGTGGTCAT-
GAG-39.
Blocking of IL-12R Induction by Anti–IFN-g mAb. Wild-type
C57BL/6 mice were injected with 500 mg i.p. anti–IFN-g mAb
(R4-6A2; PharMingen) or IL-12 (C15.1 and C15.6, donated by
Dr. G. Trinchieri, Wistar Institute of Anatomy and Biology,
Philadelphia, PA) at 0 and 1 d before priming with a-GalCer. As a1123 Kitamura et al.
control, the same amount of rat IgG1 (PharMingen) was injected
intraperitoneally into control mice before injection of a-GalCer.
Results
a-GalCer Selectively Activates NK1.11TCR-a/b1 NKT
Cells. To provide direct evidence that NKT cells are the
only target cells for activation by a-GalCer, various lym-
phoid subsets were isolated from mouse spleen cell suspen-
sions by flow cytometry and cocultured with DCs in the
presence of a-GalCer. After 36 h of culture, the superna-
tants were harvested and their IL-4 and IFN-g contents
were measured by ELISA. Fig. 1 shows that purified
NK1.11 T cells produce higher levels of IL-4 and IFN-g
than unfractionated spleen cells. The IFN-g produced in
these cultures was not derived from classical NK cells, be-
cause enrichment of NK1.11TCR-a/b2 NK cells showed
no significant cytokine production. In contrast, NK1.11
TCR-a/b1 cells, which represent the NKT cell popula-
tion, revealed markedly high levels of IL-4 and IFN-g pro-
duction. Although CD41 T cells produced higher levels of
cytokines compared with unfractionated spleen cells, this
appeared to be due to the presence of CD41NK1.11 NKT
cells, because CD41NK1.12 cells produced neither IL-4
nor IFN-g in response to a-GalCer. Culture of NK1.11
TCR-a/b1 NKT cells alone or with DCs in the absence
of a-GalCer caused no significant production of IFN-g or
IL-4, indicating that DCs are essential for the stimulation of
cytokine production by NKT cells.
Endogenous IL-12 Production by DCs Is Essential for the
Triggering of NKT Cells. Fig. 2 A shows that coculture of
DCs and NKT cells in the presence of a-GalCer results in
high levels of IFN-g production. However, addition of
anti–IL-12 mAb into these cultures caused a marked inhi-
bition of IFN-g production. Such inhibition was not ob-
served when control anti-CD8 rat IgG mAb was added.
Therefore, these results indicated that endogenously pro-
duced IL-12 by DCs was essential for the early activation of
NKT cells by a-GalCer. The effect of mAbs against CD40
and CD40L on the activation of NKT cells by a-GalCer
was also investigated (Fig. 2 B). Both anti-CD40 mAb and
anti-CD40L mAb greatly inhibited the production of IFN-g
by NKT cells in response to a-GalCer. These findings sug-
gested that direct contact between DCs and NKT cells
through CD40/CD40L interactions is critically important
Figure 1. a-GalCer selectively activates NK1.11TCR-a/b1 NKT
cells. Spleen cells from C57BL/6 mice were separated into a variety of
lymphoid cell subsets by cell sorting as described in Materials and Meth-
ods. Their responsiveness to a-GalCer in the presence of DCs was then
determined by measuring IL-4 (j) and IFN-g ( ) levels in the culture
supernatants using ELISA. As a control, NK1.11TCR-a/b1 NKT cells
were cultured alone or with DCs in the absence of a-GalCer. The bars
represent mean 6 SE of triplicate samples.
Figure 2. Endogenously produced IL-12 and CD40/CD40L interac-
tion during coculture of DCs and NKT cells is essential for NKT cell ac-
tivation by a-GalCer. Purified NKT cells were cocultured with DCs in
the presence of a-GalCer for 36 h. The IFN-g levels in culture superna-
tants were then determined by ELISA. (A) The ability of anti–IL-12 mAb
to block NKT cell activation by a-GalCer. Anti-CD8 mAb was used as
control rat IgG Ab. (B) The ability of anti-CD40 mAb and anti-CD40L
mAb to block NKT cell activation by a-GalCer. As a control, rat anti-
CD8 IgG mAb was added to the culture. (C) IL-12 production by DCs
cultured with a-GalCer and NKT cells. DCs (5 3 105) were activated
with 50 ng/ml of a-GalCer for 8 h in the presence or absence of
NK1.11TCR-a/b2 NK cells (105) or NK1.11TCR-a/b1 NKT cells
(105). The bars represent mean 6 SE of triplicate samples.1124 Immunopotentiating Mechanisms of NKT Cell Ligand a-GalCer
for the activation of NKT cells by a-GalCer. To study the
requirements for IL-12 production by DCs in these cul-
tures in further detail, IL-12 p70 activity in culture super-
natants was measured by ELISA. As shown in Fig. 2 C,
DCs produced IL-12 p70 when cultured with NKT cells
and a-GalCer. However, DCs did not produce IL-12 p70
when cultured with a-GalCer alone or when cultured
with  a-GalCer and NK (NK1.11TCR-a/b2) cells.
a-GalCer Induces IL-12R Expression on NKT Cells. The
effect of a-GalCer on the induction of IL-12R mRNA ex-
pression in spleen cells was examined by RT-PCR. As
shown in Fig. 3, intravenous injection of a-GalCer into
C57BL/6 mice caused the induction of mRNA for both
IL-12Rb1 and IL-12Rb2 in spleen cells within 4 h. This
upregulation of IL-12R was strongly blocked by adminis-
tration of anti–IL-12 mAb or anti–IFN-g mAb before in-
jection of a-GalCer (Fig. 4). Moreover, the IL-12R induc-
tion by a-GalCer was almost completely abolished in both
CD1d2/2 and Va14 NKT cell–deficient mice (Fig. 5, A
and B). Thus, these results suggested that CD1d-dependent
a-GalCer–induced IFN-g production by NKT cells may
be critically important for the upregulation of IL-12R on
NKT cells. To provide direct evidence for this hypothesis,
we measured the expression of IL-12R on purified NKT
cells that were previously activated in the presence of DCs
and a-GalCer, either in vitro or in vivo. Fig. 5 C shows
that in vitro activation of spleen cells by DCs plus a-Gal-
Cer strongly induced the expression of IL-12R on NKT
cells. Similar findings were made when mice were injected
in vivo with a-GalCer (Fig. 5 D).
a-GalCer Synergistically Acts with Exogenously Administered
IL-12 in the Activation of Natural Killing Activity and IFN-g
Production In Vivo. C57BL/6 mice were injected intrave-
nously with a-GalCer, and their splenic natural killing ac-
tivity against YAC-1 cells was determined 24 h later. As
shown in Fig. 6 A, a suboptimal dose of neither a-GalCer
nor IL-12 was able to activate natural killing activity in
vivo. However, combined administration of a-GalCer and
IL-12 at a suboptimal dose caused a marked augmentation
of natural killing.
A similar synergistic effect of a-GalCer and IL-12 was
demonstrated for the elevation of serum IFN-g produc-
tion. As shown in Fig. 6 B, the administration of a-GalCer
plus IL-12 resulted in a strong enhancement of serum IFN-g
levels in C57BL/6 mice compared with mice treated with
a-GalCer or IL-12 only.
Discussion
The finding that NKT cells recognize a-GalCer pre-
sented by DCs in a CD1d-dependent manner represents a
novel recognition mechanism in the immune system (15).
NKT cells, which can produce both IFN-g and IL-4 (16,
17), play an important role in immunoregulation and have
been considered to play a central role as innate effector cells
involved in both the protection and the onset of immune
diseases (18). The NKT cell ligand a-GalCer has a strong
immunopotentiating effect in vivo, and this chemical me-
diates strong antitumor activity (3–5, 9). Therefore, it is
important to dissect the mechanism by which a-GalCer
activates NKT cells.
The previous finding (3) that NKT-deficient mice did
not respond to a-GalCer strongly suggested that NKT cells
may be the primary target cells to a-GalCer. However, it
Figure 3. Upregulation of IL-12R expression in the spleen upon in
vivo administration of a-GalCer. C57BL/6 mice were injected intrave-
nously with a-GalCer. Various times (0, 2, 4, and 6 h) after the treat-
ment, spleen cells were prepared and their expression of IL-12Rb1 (d)
and IL-12Rb2 (s) mRNA was measured by quantitative RT-PCR. The
IL-12R mRNA levels are represented as an induction index, as described
in Materials and Methods. The bars represent mean 6 SE of triplicate
samples.
Figure 4. Role of IL-12 and IFN-g in the induction of IL-12R ex-
pression in the spleen. C57BL/6 mice were injected intravenously with
a-GalCer. 4 h after the injection, spleen cells were prepared and their ex-
pression of IL-12Rb1 ( ) and IL-12Rb2 (j) mRNA was measured by
quantitative RT-PCR. The IL-12R mRNA levels are presented as an in-
duction index, as described in Materials and Methods. The blocking ef-
fect of anti–IL-12 mAb and anti–IFN-g mAb was determined by injec-
tion of these mAbs (500 mg/mouse i.p.) into the mice 1 and 0 d before
the treatment with a-GalCer. The bars represent mean 6 SE of triplicate
samples.1125 Kitamura et al.
still remained unclear whether only NKT cells responded
to a-GalCer. To answer this question, we used highly puri-
fied splenic NK cells, NKT cells, CD41 T cells, and CD81
T cells and determined their responsiveness to a-GalCer in
the presence of DCs. The data illustrated in Fig. 1 clearly
demonstrate that NKT cells are the only cells that respond
to a-GalCer (3). It is surprising that neither classical NK
cells nor mainstream CD41 T cells or CD81 T cells re-
vealed a significant response to a-GalCer even in the pres-
ence of DCs. Together with previous findings (3), the
present data indicate that a-GalCer selectively stimulates
NKT cells in the presence of DCs.
Recently, the mechanisms of activation of naive CD41
T cells through interaction with DCs have been examined
(12, 19–22). Cell–cell adhesion between CD41 T cells and
DCs through CD40/CD40L and B7.1/CD28 resulted in
the activation of both DCs and T cells, which triggered the
production of IL-12 by DCs and IFN-g by Th1 cells (12,
19, 20, 23–25). Such conditioned DCs were able to prime
cytotoxic T cells (22, 26, 27). This recognition system has
resemblance to that discussed here. As shown in Fig. 2,
IL-12 production by DCs appears to be essential for NKT
cell activation by a-GalCer, because neutralization of en-
dogenously produced IL-12 by anti–IL-12 mAb caused a
strong inhibition of IFN-g production by NKT cells. The
important role of CD40/CD40L for the production of
IFN-g in the cocultures of DCs and NKT cells with
a-GalCer is also apparent from these experiments (Fig. 2
B). As demonstrated in Fig. 2 C, DCs produce IL-12 only
when they are cultured with a-GalCer in the presence of
NKT cells, indicating that direct contact between a-Gal-
Cer–bound DCs and NKT cells may be essential for IL-12
production by DCs. This interaction may be required for
the production of IFN-g by IL-12–activated NKT cells,
because mAbs directed against CD40/CD40L greatly in-
hibited IFN-g production by NKT cells (Fig. 2). These
findings indicate that the interaction of NKT cells with
DCs may be very similar to the interaction of helper T cells
with DCs (22, 26, 27). Since the interactions between DCs
and NKT cells occur very quickly after administration of
a-GalCer, NKT cells may be able to condition DCs very
early in an immune response, and affect subsequent adap-
tive responses.
In this paper, we also demonstrate that a-GalCer upreg-
ulates IL-12R expression in vivo (Fig. 3). IL-12R upregu-
lation is blocked by mAbs against IL-12 or IFN-g and is
absent in CD1d2/2 and NKT-deficient mice (Figs. 4 and
5). Moreover, activation of NKT cells in vitro and in vivo
results in a strong induction of IL-12Rb1 and IL-12Rb2
on these cells (Fig. 5, C and D). Therefore, we speculate
that the following series of events is induced upon culture
of a-GalCer with DCs and NKT cells: (a) a-GalCer first
binds to CD1d molecules on DCs; (b) NKT cells recognize
a-GalCer–bound DCs via their TCRs and also interact
with DCs via CD40/CD40L; (c) during this interaction,
DCs produce IL-12; (d) the endogenously produced IL-12
stimulates IFN-g production by NKT cells; and (e) IFN-g
produced by NKT cells upregulates IL-12R on NKT cells
in an autocrine manner. The dramatic synergistic effect of
Figure 5. a-GalCer induces IL-12R expression on NKT cells.
C57BL/6 wild-type mice, CD1d2/2 mice, and NKT-deficient mice
were injected intravenously with vehicle ( ) or a-GalCer (j). 4 h after
the injection, spleen cells were prepared and their expression of IL-
12Rb1 (A) and IL-12Rb2 (B) mRNA was measured by quantitative
RT-PCR. (C) Spleen cells from wild-type mice were cultured with DCs
plus a-GalCer or vehicle for 8 h, NK1.11TCR-a/b1 NKT cells were
purified by cell sorting, and the expression of IL-12Rb1 ( ) and IL-
12Rb2 (j) was examined by quantitative RT-PCR. (D) Wild-type mice
were injected intravenously with a-GalCer or vehicle; after 6 h the
spleens from these mice were isolated, and NK1.11TCR-a/b1 NKT
cells were purified by cell sorting, and expression of IL-12Rb1 ( ) and
IL-12Rb2 (j) was examined by quantitative RT-PCR. The IL-12R
mRNA levels are presented as an induction index, as described in Materi-
als and Methods. The bars represent mean 6 SE of triplicate samples.
Figure 6. Synergistic effect of a-GalCer and IL-12 in vivo. C57BL/6
mice were injected with a suboptimal dose of a-GalCer (200 ng/mouse
i.v.) and 6 h later, mice were injected with a suboptimal dose of IL-12
(200 U/mouse i.p.). 1 d after the treatment with IL-12, the mice were
killed and splenic natural killing activity (A) and serum IFN-g levels (B)
were determined as described in Materials and Methods. The bars repre-
sent mean 6 SE of triplicate samples.1126 Immunopotentiating Mechanisms of NKT Cell Ligand a-GalCer
suboptimal a-GalCer and exogenously administered IL-12
indicates that expression of IL-12Rb1 and b2, detected by
quantitative RT-PCR, is functionally upregulated in vivo.
Moreover, since this synergistic effect of a-GalCer and IL-
12 was not demonstrated in NKT-deficient mice, we con-
clude that in wild-type mice coadministration of a-GalCer
and IL-12 leads to upregulation of IL-12R on CD1-depen-
dent NKT cells.
Both a-GalCer and IL-12 have been demonstrated to
exhibit potent antitumor activity in vivo. IL-12 has multi-
ple effects on the immune system that are beneficial for the
induction of antitumor immunity in vivo (28–30). How-
ever, the unexpected severe side effects of IL-12 have made
it difficult to use this cytokine in clinical trials (31). We
demonstrated that a-GalCer synergistically acts with small
doses of IL-12 in vivo to activate NKT cells and to induce
IFN-g production (Fig. 6). These findings suggest that
coadministration of a-GalCer with IL-12 could be used as
a new approach for tumor immunotherapy.
Recent studies have demonstrated that Th1 immunity reg-
ulated by IL-12 and IFN-g plays a critical role in the induc-
tion of protective immunity against tumors and infectious
agents (32, 33). Although NKT cells are involved in both
Th1 and Th2 immunity through IFN-g or IL-4 production,
the immunomodulating protocol using a-GalCer and IL-12
preferentially induces NKT cells that produce large amounts
of IFN-g (34). These NKT cells may facilitate the develop-
ment of Th1-dominant cellular immunity essential for the in-
duction of protective immunity against tumors and some in-
fectious agents. Recently, it was demonstrated that a-GalCer
can stimulate human NKT cells in a CD1d-dependent man-
ner (35, 36), indicating that our proposed immunotherapy
protocol using a-GalCer and IL-12 will be useful for the ap-
plication to human immune diseases, including cancer.
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